転移性去勢耐性前立腺癌(MCRPC)の患者におけるHLD-0915の研究
転移性去勢耐性前立腺癌(MCRPC)の患者におけるHLD-0915の第1/2フェーズ研究
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80909
- 募集
- Rocky Mountain Cancer Center
-
Denver、Colorado、アメリカ、80218
- 募集
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- 募集
- Yale University
-
-
Florida
-
Sarasota、Florida、アメリカ、34232
- 募集
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- 募集
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49546
- 募集
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Urology Cancer Center, PC
-
-
New York
-
Long Island City、New York、アメリカ、11101
- 募集
- Memorial Sloan Kettering Cancer Center
-
Syracuse、New York、アメリカ、13210
- 募集
- Associated Medical Professionals
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach、South Carolina、アメリカ、29572
- 募集
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Sarah Cannon Research Institute
-
Nashville、Tennessee、アメリカ、37209
- 募集
- Urology Associates
-
-
Texas
-
Austin、Texas、アメリカ、78758
- 募集
- NEXT Oncology
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23502
- 募集
- Virginia Clinical Research
-
-
-
-
-
Sutton、イギリス、SM2 5PT
- 募集
- The Royal Marsden NHS Trust
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
実験的:JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
実験的:JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
実験的:Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
実験的:Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
実験的:Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
実験的:Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
時間枠:21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
時間枠:21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
時間枠:22 days
|
22 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK Parameters
時間枠:21 days
|
21 days
|
|
|
Duration of Response (DOR)
時間枠:21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
時間枠:63 days
|
63 days
|
|
|
Time to Response (TTR)
時間枠:63 days
|
63 days
|
|
|
Change in PSA over time
時間枠:21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
時間枠:63 days
|
Per RECIST in evaluable patients |
63 days
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (その他の識別子:Janssen Research & Development, LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。